By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit

Key Statistics

Ownership: Private

Web Site: Acucela


Company News
Acucela Validates Sampling Method That Could Pave Way For More Efficient Clinical Tests 11/4/2015 10:22:49 AM
Dr. George Lasezkay Joins Acucela as Executive Vice President, Legal Affairs 8/25/2015 9:30:22 AM
Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine 8/6/2015 11:37:57 AM
Acucela Announces Publication Of Phase 2a Clinical Trial Results For Emixustat Hydrochloride 6/4/2015 8:40:50 AM
Acucela Nominates Shintaro Asako To Its Board Of Directors 5/19/2015 10:11:12 AM
Acucela Announces Publication Of Pre-clinical Data For Emixustat Hydrochloride 5/14/2015 9:25:10 AM
EXCLUSIVE: Reinstated Acucela CEO Tells BioSpace (DHX) "Shareholders Made Their Choice" 5/7/2015 10:19:00 AM
Acucela Founder Regains Top Spot at Company After Shareholder’s Meeting 5/4/2015 6:10:47 AM
Acucela Provides Important Company Updates 4/27/2015 11:26:15 AM
Acucela Granted New Patent Covering Method Of Use For Emixustat Hydrochloride 4/1/2015 12:33:02 PM